Leland Gershell
Stock Analyst at Oppenheimer
(4.58)
# 231
Out of 5,091 analysts
146
Total ratings
51.08%
Success rate
33.61%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $28.56 | +89.08% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $12.98 | +84.90% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $8.36 | +294.74% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $6.99 | +157.51% | 5 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $31.88 | +12.92% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $47.40 | +83.54% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $20.01 | +299.80% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $51.18 | +114.93% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $74.24 | -17.83% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $430.02 | +13.95% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $9.45 | +111.64% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $105.18 | +4.58% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $207.12 | +8.15% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $23.08 | +34.32% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.81 | +452.49% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $900.76 | -21.40% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.90 | +156.41% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $53.30 | +83.86% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $43.60 | +19.27% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.65 | +1,786.79% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $23.17 | +128.74% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.55 | +238.03% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $4.14 | +120,672.95% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.72 | +337.06% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $4.41 | +353.51% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $23.16 | +25.22% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $19.44 | +80.04% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.53 | +1,792.86% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.90 | +2,126.43% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.66 | +388.72% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.84 | +3,025.00% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.86 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $28.33 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.93 | +5,276.34% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.92 | - | 5 | Mar 31, 2020 |
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $28.56
Upside: +89.08%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $12.98
Upside: +84.90%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $8.36
Upside: +294.74%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $6.99
Upside: +157.51%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $31.88
Upside: +12.92%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $47.40
Upside: +83.54%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $20.01
Upside: +299.80%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $51.18
Upside: +114.93%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $74.24
Upside: -17.83%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $430.02
Upside: +13.95%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $9.45
Upside: +111.64%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $105.18
Upside: +4.58%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $207.12
Upside: +8.15%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $23.08
Upside: +34.32%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.81
Upside: +452.49%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $900.76
Upside: -21.40%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $3.90
Upside: +156.41%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $53.30
Upside: +83.86%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $43.60
Upside: +19.27%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.65
Upside: +1,786.79%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $23.17
Upside: +128.74%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.55
Upside: +238.03%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $4.14
Upside: +120,672.95%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.72
Upside: +337.06%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $4.41
Upside: +353.51%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $23.16
Upside: +25.22%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $19.44
Upside: +80.04%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.53
Upside: +1,792.86%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.90
Upside: +2,126.43%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.66
Upside: +388.72%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.84
Upside: +3,025.00%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.86
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $28.33
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $0.93
Upside: +5,276.34%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.92
Upside: -